Adenosine as putative regulator of hepatic arterial flow (the buffer response).
In anesthetized cats, reduction of portal flow by occlusion of the superior mesenteric artery results in rapid increase in hepatic arterial (HA) flow that compensates for (buffers) 25.5 +/- 2.7% of the decreased portal flow. The hypothesis tested is that adenosine concentration produced near the HA resistance vessels is regulated by washout into portal vessels in intimate contact with the HA. Reduced portal flow leads to accumulation of adenosine and HA dilation. Several criteria for this hypothesis are met. First, adenosine is a potent dilator of the HA. Second, portal blood has access to HA resistance vessels as shown by a marked dilator effect of adenosine infused into the portal vein; it is therefore possible for adenosine produced locally to diffuse into portal blood. Third, dipyridamole potentiated the dilator response to adenosine as well as potentiating the buffer response from a 23% compensation for reduced portal flow to 34%. Fourth, 1-methyl-3-isobutylxanthine (MIX) antagonized exogenous adenosine and reduced the buffer response from 19% down to 5%. These data strongly support the hypothesis that the hepatic arterial buffer response is mediated by local concentrations of adenosine that are controlled by the rate of washout into portal blood.
Lautt
W W
WW
Legare
D J
DJ
d'Almeida
M S
MS
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D015762:2-Chloroadenosine; D000241:Adenosine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000502:physiology*; D000818:Animals; D001794:Blood Pressure; D002415:Cats; D004176:Dipyridamole / Q000494:pharmacology; D006499:Hepatic Artery / Q000502:physiology*; D008102:Liver Circulation; D011168:Portal System; D012212:Rheology; D013997:Time Factors; D014664:Vasodilation
D015762:2-Chloroadenosine; D004176:Dipyridamole; D000241:Adenosine; D015056:1-Methyl-3-isobutylxanthine